...
首页> 外文期刊>Drug safety: An international journal of medical toxicology and drug experience >Readability assessment of package inserts of biological medicinal products from the European Medicines Agency website
【24h】

Readability assessment of package inserts of biological medicinal products from the European Medicines Agency website

机译:欧洲药品管理局网站上的生物药品包装说明书的可读性评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Package inserts that accompany medicines are a common source of information aimed at patients and should match patient abilities in terms of readability. Objective: Our objective was to determine the degree of readability of the package inserts for biological medicinal products commercially available in 2007 and compare them with the readability of the same package inserts in 2010. Methods: A total of 33 package inserts were selected and classified into five groups according to the type of medicine: monoclonal antibody-based products, cytokines, therapeutic enzymes, recombinant blood factors and other blood-related products, and recombinant hormones. The package inserts were downloaded from the European Medicines Agency website in 2007 and 2010. Readability was evaluated for the entire text of five of the six sections of the package inserts and for the 'Annex' when there was one. Three readability formulas were used: SMOG (Simple Measure of Gobbledygook) grade, Flesh-Kincaid grade level, and Szigriszt's perspicuity index. Results: No significant differences were found between the readability results for the 2007 package inserts and those from 2010 according to any of the three readability indices studied (p > 0.05). However, there were significant differences (p < 0.05) between the readability scores of the sections of the package inserts in both 2007 and 2010. The readability of the package inserts was above the recommended sixth grade reading level (ages 11-12) and may lead to difficulties of understanding for people with limited literacy. Conclusions: All the sections should be easy to read and, therefore, the readability of the medicine package inserts studied should be improved.
机译:背景:药品随附的包装插页是针对患者的常见信息来源,在可读性方面应与患者的能力相匹配。目的:我们的目标是确定2007年市售的生物医药产品包装插页的可读性,并将其与2010年相同包装插页的可读性进行比较。方法:总共选择了33种包装插页,并分为根据药物类型分为五类:基于单克隆抗体的产品,细胞因子,治疗性酶,重组血液因子和其他与血液有关的产品以及重组激素。从2007年和2010年从欧洲药品管理局网站下载了包装说明书。对包装说明书的六个部分中的五个部分的全文和“附件”(如果有)的可读性进行了评估。使用了三个可读性公式:SMOG(简单测量的Gobbledygook)等级,Flesh-Kincaid等级等级和Szigriszt的透视指数。结果:根据所研究的三个可读性指数中的任何一项,2007年包装插页的可读性结果与2010年以来的可读性结果之间均未发现显着差异(p> 0.05)。但是,包装插页的各个部分在2007年和2010年的可读性评分之间存在显着差异(p <0.05)。包装插页的可读性高于建议的六年级阅读水平(11至12岁),可能导致识字能力有限的人难以理解。结论:所有部分均应易于阅读,因此,应提高所研究药物包装插页的可读性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号